507 - The PAAB does not allow the use of post-hoc study analyses to support claims. Are there any exceptions to this? For example if the post-hoc analysis was done for safety reasons at the request of the FDA, would that publication be permitted to support claims?
-
Post hoc analysis is not accepted as evidentiary support for claims of benefit (PAAB s 3.1.1). The only exception which readily comes to mind is if the data is in the Health Canada approved Terms of Market Authorization.
